Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Abdallah on Interim Efficacy Data on HPN217 in R/R Multiple Myeloma

December 23rd 2022

Al-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr Carlo-Stella on Updated Results on RG6234 Activity in R/R Multiple Myeloma

December 23rd 2022

Carmelo Carlo-Stella, MD, PhD, discusses updated results from a phase 1 dose-escalation study of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Dr. Kumar on Updated Data from the MAIA Trial in Newly Diagnosed Multiple Myeloma

December 23rd 2022

Shaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.

Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

December 22nd 2022

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

December 22nd 2022

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Dr Kumar, Dr Patel, Falbo, and Ahlstrom highlight the importance of community-based discussions regarding adverse effects in multiple myeloma, the benefits of considering the whole treatment course, and subgroup analyses from the MAIA trial.

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

December 22nd 2022

Dr Ajay Chari reviews the results from the MonumenTAL-1 trial which evaluates the use of talquetamab, a GPRC5D x CD3 bispecific antibody in patients with relapsed refractory multiple myeloma.

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study

December 22nd 2022

Shaji Kumar, MD, reviews the results of the phase 3 study evaluating the use of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

Induction Regimen Options for Patients with Transplant-Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

December 19th 2022

Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.

Introduction to Multiple Myeloma and Resources for Patient Education after Diagnosis

December 19th 2022

Shaji Kumar, MD, provides an overview of multiple myeloma, and Jenny Ahlstrom, a patient with multiple myeloma, shares the story of her diagnosis and the resources she used to educate herself.

Dr. Susanibar on Important Considerations When Treating Multiple Myeloma

December 14th 2022

Sandra P. Susanibar-Adaniya, MD, discusses important considerations when treating patients with multiple myeloma.

BCMA/CD19 Dual-targeting CAR T-cell Therapy Shows 100% MRD Negativity Rate in Newly Diagnosed Multiple Myeloma

December 13th 2022

Among patients with newly diagnosed high-risk multiple myeloma, treatment with BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100%, with all treated patients evaluable for minimal residual disease showing minimal residual disease negativity to 12 months.

Cilta-Cel Shows Efficacy and Tolerability in Multiple Myeloma, Potentially Filling Unmet Need in Early-Line Therapy

December 13th 2022

The CAR-T cell therapy ciltacabtagene autoleucel has expanded options for adult patients with relapsed/refractory multiple myeloma after 4 or more lines of prior therapy in the United States, and has continued to display promising efficacy in patients with multiple myeloma following early relapse.

Amid Withdrawal News, Final DREAMM-2 Analysis Confirms Durability of Belantamab Mafotodin Monotherapy in Relapsed/Refractory Multiple Myeloma

December 12th 2022

Single-agent belantamab mafodotin continued to produce rapid, deep, and durable responses in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Prolongs PFS, Compared With Historical Control in Relapsed/Refractory Multiple Myeloma

December 12th 2022

The combination of belantamab mafodotin, pomalidomide, and dexamethasone elicited encouraging responses and survival benefits in patients with triple class–exposed or refractory multiple myeloma.

Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro Nakamura

December 12th 2022

In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.

Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple Myeloma

December 12th 2022

Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr Berdeja on the Safety and Efficacy of BMS-986393 in R/R Multiple Myeloma

December 11th 2022

Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.

GRIFFIN Patient-Reported Outcomes Data Support Frontline Daratumumab-Quadruplet Therapy in Transplant Eligible, Newly Diagnosed, Multiple Myeloma

December 11th 2022

Daratumumab in addition to bortezomib, lenalidomide, and dexamethasone induction/consolidation therapy, as well as with lenalidomide maintenance, showcased a promising health-related quality of life benefit for patients with transplant eligible, newly diagnosed multiple myeloma.

Mezigdomide Shows Encouraging Activity With Dexamethasone in Heavily Pretreated Patients With Multiple Myeloma

December 11th 2022

Mezigdomide showed notable clinical activity and a manageable safety profile when combined with dexamethasone in patients with triple-class relapsed or refractory multiple myeloma.